share_log
Breakings ·  Jul 2 20:00
Annovis Bio Announces New Data From Phase III Parkinson’s Study Highlighting Improvements in Unified Parkinson's Disease Rating Scale (Mds-Updrs) and Cognition After Treatment With Buntanetap
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment